array:21 [
  "pii" => "X2013251414054636"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2014.Jun.12327"
  "estado" => "S300"
  "fechaPublicacion" => "2014-09-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2014;34:570-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 7324
    "formatos" => array:3 [
      "EPUB" => 336
      "HTML" => 6148
      "PDF" => 840
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699514054639"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2014.Jun.12327"
      "estado" => "S300"
      "fechaPublicacion" => "2014-09-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2014;34:570-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 11353
        "formatos" => array:3 [
          "EPUB" => 323
          "HTML" => 10117
          "PDF" => 913
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "titulo" => "Impacto de la inmunosupresión en la mejora de la supervivencia del injerto tras un transplante renal de donante cadáver: estudio de cohorte a largo plazo"
        "tienePdf" => "es"
        "tieneTextoCompleto" => 0
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "570"
            "paginaFinal" => "578"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Impact of immunosuppression treatment on the improvement in graft survival after deceased donor renal transplantation: a long-term cohort study"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Miguel González-Molina, Dolores Burgos, Mercedes Cabello, Pedro Ruiz-Esteban, Manuel A. Rodríguez, Cristina Gutiérrez, Verónica López, Víctor Baena, Domingo Hernández"
            "autores" => array:9 [
              0 => array:2 [
                "nombre" => "Miguel"
                "apellidos" => "González-Molina"
              ]
              1 => array:2 [
                "nombre" => "Dolores"
                "apellidos" => "Burgos"
              ]
              2 => array:2 [
                "nombre" => "Mercedes"
                "apellidos" => "Cabello"
              ]
              3 => array:2 [
                "nombre" => "Pedro"
                "apellidos" => "Ruiz-Esteban"
              ]
              4 => array:2 [
                "nombre" => "Manuel A."
                "apellidos" => "Rodríguez"
              ]
              5 => array:2 [
                "nombre" => "Cristina"
                "apellidos" => "Gutiérrez"
              ]
              6 => array:2 [
                "nombre" => "Verónica"
                "apellidos" => "López"
              ]
              7 => array:2 [
                "nombre" => "Víctor"
                "apellidos" => "Baena"
              ]
              8 => array:2 [
                "nombre" => "Domingo"
                "apellidos" => "Hernández"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251414054636"
          "doi" => "10.3265/Nefrologia.pre2014.Jun.12327"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054636?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054639?idApp=UINPBA000064"
      "url" => "/02116995/0000003400000005/v0_201502091337/X0211699514054639/v0_201502091337/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251414054628"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Jun.12422"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2014;34:579-83"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6136
      "formatos" => array:3 [
        "EPUB" => 301
        "HTML" => 4924
        "PDF" => 911
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Study on overhydration in dialysis patients and its association with inflammation"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "579"
          "paginaFinal" => "583"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Estudio de sobrehidratación en los pacientes en diálisis y su relación con la inflamación"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12422_16025_61167_en_t112422i.jpg"
              "Alto" => 1723
              "Ancho" => 1074
              "Tamanyo" => 249080
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Descriptive baseline characteristics"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Almudena Vega, Borja Quiroga, Soraya Abad, Caridad Ruiz, Juan M. López-Gómez"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Almudena"
              "apellidos" => "Vega"
            ]
            1 => array:2 [
              "nombre" => "Borja"
              "apellidos" => "Quiroga"
            ]
            2 => array:2 [
              "nombre" => "Soraya"
              "apellidos" => "Abad"
            ]
            3 => array:2 [
              "nombre" => "Caridad"
              "apellidos" => "Ruiz"
            ]
            4 => array:2 [
              "nombre" => "Juan M."
              "apellidos" => "López-Gómez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054620"
        "doi" => "10.3265/Nefrologia.pre2014.Jun.12422"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054620?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054628?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054628/v0_201502091605/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251414054644"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Apr.12481"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2014;34:561-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 10092
      "formatos" => array:3 [
        "EPUB" => 325
        "HTML" => 8826
        "PDF" => 941
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Cardiovascular mortality: how can it be prevented?"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "561"
          "paginaFinal" => "569"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Mortalidad cardiovascular: ¿cómo prevenirla?"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12481_16025_59949_en_f112481i.jpg"
              "Alto" => 1154
              "Ancho" => 2103
              "Tamanyo" => 434852
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Mediterranean diet pyramid created by the Meditarranean Diet Foundation of Barcelona (2010) (Source: Mediterranean Diet Foundation, www.dfmed.org)22."
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ramón Estruch, Ramon Estruch"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Ramón"
              "apellidos" => "Estruch"
            ]
            1 => array:2 [
              "nombre" => "Ramon"
              "apellidos" => "Estruch"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054647"
        "doi" => "10.3265/Nefrologia.pre2014.Apr.12481"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054647?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054644?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054644/v0_201502091605/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Impact of immunosuppression treatment on the improvement in graft survival after deceased donor renal transplantation: a long-term cohort study"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "570"
        "paginaFinal" => "578"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Miguel González-Molina, Dolores Burgos, Mercedes Cabello, Pedro Ruiz-Esteban, Manuel A. Rodríguez, Cristina Gutiérrez, Verónica López, Víctor Baena, Domingo Hernández"
        "autores" => array:9 [
          0 => array:4 [
            "nombre" => "Miguel"
            "apellidos" => "González-Molina"
            "email" => array:1 [
              0 => "mgonmol@yahoo.es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Dolores"
            "apellidos" => "Burgos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Mercedes"
            "apellidos" => "Cabello"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Pedro"
            "apellidos" => "Ruiz-Esteban"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Manuel A&#46;"
            "apellidos" => "Rodr&#237;guez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Cristina"
            "apellidos" => "Guti&#233;rrez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Ver&#243;nica"
            "apellidos" => "L&#243;pez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "V&#237;ctor"
            "apellidos" => "Baena"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Domingo"
            "apellidos" => "Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => " Servicio de Nefrología, Hospital Regional Universitario Carlos Haya/IBIMA, Málaga,   "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => " Servicio de Nefrología, Hospital Torrecárdenas, Almería,   "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => " Servicio de Urología, Hospital Regional Universitario Carlos Haya, Málaga,   "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Impacto de la inmunosupresi&#243;n en la mejora de la supervivencia del injerto tras un transplante renal de donante cad&#225;ver&#58; estudio de cohorte a largo plazo"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52257_en_12327_t1.jpg"
            "Alto" => 579
            "Ancho" => 698
            "Tamanyo" => 341081
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Since the introduction of cyclosporine &#40;CsA&#41; controversy has surrounded the long-term results of renal transplantation &#40;RT&#41;&#46; The most accepted theory is derived from an observational study of kidney transplant recipients who received their grafts between 1988 and 1995&#59; this study showed a significant increase in graft survival during the first year&#44; but only a marginal increase in the long term&#46;<span class="elsevierStyleSup">1</span> These data demonstrated that&#44; despite CsA reducing the incidence of acute rejection &#40;AR&#41;&#44; RT remained a limited option in terms of survival&#44; with the continued loss of grafts&#46;</p><p class="elsevierStylePara">Other single center<span class="elsevierStyleSup">2</span> and multicenter<span class="elsevierStyleSup">3&#44;4</span> studies including transplant recipients who received their grafts after 1995 and whose immunosuppression included the new agents mycophenolate mofetil &#40;MMF&#41; and tacrolimus &#40;TaC&#41; found an increased long-term graft survival&#44; or at least showed a significant improvement in the rate of decline in long-term kidney allograft function in recent years&#46;<span class="elsevierStyleSup">5</span> In any case&#44; long-term graft loss remained an important problem in kidney transplant recipients&#44; due mainly to calcineurin inhibitor &#40;CNI&#41; toxicity-mediated allograft damage&#46;<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">Later&#44; other authors provided data showing that graft loss due to nephrotoxicity was less usual than previously considered&#44; though it was nevertheless common after antibody-mediated rejection&#44; glomerulonephritis and nonadherence to the treatment&#46;<span class="elsevierStyleSup">7&#44;8</span> This represented a new approach to the causes of graft loss&#44; and obliged us to determine whether the introduction of the potent new immunosuppressive agents MMF and TaC improved the results of RT in terms of survival&#46; The aim&#44; therefore&#44; of this study was to assess whether the long-term RT outcome has improved under modern immunosuppression in a cohort study derived from a single transplant center&#46; Given that important immunosuppressive changes occurred in 1996&#44; we arbitrarily divided our cohort population into two periods &#40;1986-1995 and 1996-2001&#41; in order to perform a more detailed and real analysis of factors associated with RT outcome&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">MATERIALS AND METHODS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Study design</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">This retrospective cohort study was carried out at a single transplant center&#46; We pooled data from all adult patients &#40;&#62;18 years&#41; who received a primary or repeat deceased donor transplantation from January 1986 to December 2001 at Carlos Haya University Hospital &#40;Malaga&#44; Spain&#41;&#44; with a follow-up to December 2011&#46; Thus&#44; the minimum and maximum follow-up times were 10 years and 25 years&#44; respectively&#46; Only 17 &#40;1&#46;6&#37;&#41; patients had an incomplete follow-up during the whole study period&#46; Patients with a living donor or double transplant &#40;combined kidney-pancreas or kidney-liver&#41; were excluded&#46;</p><p class="elsevierStylePara">The endpoint of the study was to analyze the graft survival and the attrition rates stratified by year of transplantation in recipients who received different immunosuppressive regimens&#46; We also assessed the patient survival rate and the evolution of renal allograft function&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Immunosuppression</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">Table 1 shows the immunosuppressive treatment in our cohort population by study period&#58; 1986-95 versus 1996-01&#46; Most patients in the first period received CsA plus prednisone &#40;P&#41;&#46; Thereafter&#44; MMF was added in the majority of immunosuppressive treatments&#44; as well as TaC instead of CsA with effect from 1999&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Clinical variables</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The study variables included cause of donor death &#40;trauma or stroke&#41;&#44; age and gender of the donor and the recipient&#44; body mass index&#44; first or retransplantation&#44; time on dialysis&#44; panel-reactive antibody &#40;PRA&#41; at peak and at transplantation&#44; HLA mismatches&#44; cold ischemia time &#40;CIT&#41;&#44; the presence of delayed graft function &#40;DGF&#41;&#44; AR&#44; type of immunosuppressive therapy&#44; graft function&#44; graft and patient survival&#44; graft half-life&#44; and graft attrition rates&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Attrition rates</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">To calculate the attrition rates&#44; we first obtained the actual 0-1 year&#44; 1-3 year&#44; 3-5 year and 5-10 year survival rates&#46; We then subtracted the number of patients with graft failure during the time period from the original number of patients in the cohort&#46; The resulting number was then divided by the original number in the cohort to obtain an absolute failure percentage&#46; This percentage of absolute failures was divided by the total number of years in the follow-up interval&#44; with which we obtained the yearly failure rates&#46;<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Renal function</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The estimated glomerular filtration rate &#40;GFR&#58; mL&#47;min&#46;&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#41;&#44; based on the serum creatinine concentration&#44; was obtained using the abbreviated Modification of Diet in Renal Disease &#40;aMDRD&#41; equation<span class="elsevierStyleSup">9</span> at three months and annually&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Institutional review and patient protection</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">Medical record review was performed according to the Spanish law on clinical data confidentiality&#46; This study was approved by the ethics committee of the hospital and was conducted according to the principles described in the Declaration of Helsinki&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical analyses</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">A descriptive analysis was made&#44; obtaining the mean and the standard deviation for the quantitative variables and the relative frequency for the qualitative variables&#46; Hypothesis contrast tests used included the Student t test or Mann-Whitney test for quantitative variables and the &#935;<span class="elsevierStyleSup">2</span> test or Fisher test for qualitative variables&#46;</p><p class="elsevierStylePara">Kaplan-Meier survival curves were used to assess the unadjusted half-lives and survival rates for both death-censored and uncensored graft survival&#46; The graft half-life was calculated as the median survival&#44; i&#46;e&#46;&#44; the cut point or intersection on the Kaplan-Meier curve with the 50&#37; threshold&#46; The graft half-life was considered to be real if all the patients reached this point and actuarial if only some reached this point&#46; The log-rank test was used to compare survival curves&#46;</p><p class="elsevierStylePara">The Cox proportional regression model was used to estimate the risk factors for graft loss during the follow-up period&#44; with backward stepwise regression&#44; i&#46;e&#46;&#44; starting with all the possible variables and interactions that could influence the model&#46; The variables were then eliminated if their presence failed to improve the quality of the model&#44; choosing always the most parsimonious model&#44; which finally included just those variables giving a more precise prediction&#46;</p><p class="elsevierStylePara">Covariates used to calculate the adjusted Cox multivariate proportional hazards models included donor and recipient age&#44; AR&#44; CIT&#44; DGF&#44; PRA&#44; cause of donor death&#44; HLA mismatches&#44; period of RT &#40;1996-01 vs&#46; 1986-95&#41; and immunosuppression &#40;CsA&#44; MMF&#44; TaC and induction with poly- and monoclonal antibodies&#41;&#46; The proportionality of the exploratory variables in the model was assessed by visual inspection of the log-log survival plots&#46;</p><p class="elsevierStylePara">The statistical analyses were done with SPSS &#40;IBM&#44; Chicago&#44; IL&#44; version 15&#41; for Windows &#40;Microsoft&#44; Redmond&#44; WA&#41;&#44; and EPIDAT 3&#46;1 &#40;Programa para analisis epidemiologico de datos tabulados&#59; Xunta de Galicia&#44; Santiago de Compostela&#44; Spain&#41;&#44; and significance was set at P&#60;0&#46;05&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">We analyzed a total of 1045 adult cadaveric donor kidney transplant recipients between 1986 and 2001&#46; Most of the patient and donor demographic and clinical characteristics varied between the two study periods &#40;Table 1&#41;&#46; Significant increases were found in donor and recipient age&#44; donor death from stroke&#44; and number of HLA mismatches in the second period&#46; In contrast&#44; a significant reduction was seen in PRA&#44; incidence of AR&#44; and CIT in the second period&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Graft survival</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The global actuarial graft half-life was 11&#46;5 years&#46; The real graft half-life in patients with AR was 7&#46;7 years and in those without AR the actuarial graft half-life was 15 years &#40;P&#60;0&#46;001&#41;&#46;</p><p class="elsevierStylePara">The Kaplan-Meier curve showed a significant increase in uncensored and death-censored graft survival during the second period &#40;Figure 1 and Figure 2&#41;&#46; The real uncensored graft half-life was 10&#46;25 years in the first period and the actuarial graft half-life was 14&#46;58 years in the second period &#40;P&#60;0&#46;001&#41;&#46; For the censored cases&#44; the actuarial graft half-life was 14&#46;83 years in the first period&#44; whereas at this point in those patients transplanted during the second period 61&#46;3&#37; still had a functioning graft&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Graft attrition rate &#37;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The attrition rate &#37;&#44; censored and uncensored&#44; showed a continuous loss of grafts over time in both periods&#44; significantly greater in the first period &#40;Table 2&#41;&#46; These differences remained after excluding the first year from the analysis &#40;P&#61;0&#46;0018 and P&#61;0&#46;0001&#44; respectively&#41;&#46; Similarly&#44; patients who received CsA&#43;MMF&#43;P showed a significantly lower rate of graft loss compared with patients on CsA&#43;P in both the uncensored &#40;P&#61;0&#46;0009&#41; and censored &#40;P&#61;0&#46;001&#41; cases&#46; No significant differences were seen in graft survival between CsA and TaC&#46;</p><p class="elsevierStylePara">The Cox univariate and multivariate models showed that donor age and AR were the only risk factors that were significantly associated with graft loss in both periods of the study &#40;Table 3&#41;&#46;</p><p class="elsevierStylePara">The parsimonious Cox multivariate model showed that donor age&#44; AR&#44; PRA&#44; CIT and DGF were significantly associated with a higher risk for graft loss &#40;Table 4&#41;&#46; In contrast&#44; the risk of graft loss fell by 21&#37; in the period 1996-01 compared with the period 1986-95 &#40;Table 4&#41;&#46; Given that most patients &#40;72&#46;20&#37;&#41; transplanted during the period 1996-01 received MMF&#44; we entered into the final model MMF treatment instead of study period&#46; Notably&#44; the use of MMF was associated with a similar reduction in the risk for graft loss &#40;HR 0&#46;758&#44; 95&#37; CI 0&#46;623-0&#46;924&#59; P&#61;0&#46;006&#41;&#44; whereas neither the use of CsA vs&#46; TaC nor induction with poly- and monoclonal antibodies showed significant differences in graft survival&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Patient survival</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">No significant differences were found in patient survival between the two study periods&#46; The 10-year patient survival was 83&#46;2&#37; in the first period and 83&#46;3&#37; in the second period &#40;P&#61;0&#46;432&#41;&#44; even though the recipient age was significantly higher in the latter period&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Renal function</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The GFR was significantly better in the second period with effect from the third month post-transplant&#46; At this third month post-transplant&#44; a higher GFR was observed in patients transplanted in 1986-95 compared with 1996-01 &#40;51&#46;4&#177;20&#46;0 vs&#46; 48&#46;3&#177;19&#46;6mL&#47;min&#46;&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#59; P&#61;0&#46;01&#41;&#46; However&#44; with effect from the first year post-transplant the renal function was significantly better in the second study period&#44; despite a higher donor age in this period &#40;Table 5&#41;&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">For years the concept has prevailed that graft survival after kidney transplantation has increased in the first year but not over the long term&#46; That is&#44; progress had been made during the early phase of RT&#44; a stage in which T-cell mediated rejection and acute kidney injury predominate&#44;<span class="elsevierStyleSup">8</span> but problems still existed over the longer term that limited the half-life of the graft&#46; Among the causes of this failure&#44; CNI nephrotoxicity was considered a determining factor&#46;<span class="elsevierStyleSup">6</span> This suggestion was supported by authors who found chronic lesions in the native kidneys of recipients of other organs &#40;not kidney&#41; who were treated with CNI&#46;<span class="elsevierStyleSup">10</span></p><p class="elsevierStylePara">Nowadays&#44; though&#44; whilst still recognizing the nephrotoxic effect of CNI&#44; it is not universally accepted that the chronic lesions attributed to CNI are caused solely by these drugs&#46;<span class="elsevierStyleSup">11-13</span> After analyzing the causes of long-term graft loss&#44; others have shown that in cases with fibrosis&#47;atrophy a specific cause was identified in 81&#37; and it was rarely attributable to CNI toxicity alone&#44;<span class="elsevierStyleSup">14</span> cell mediated rejection&#44; or acute kidney injury&#46;<span class="elsevierStyleSup">8</span> Graft loss was&#44; however&#44; more common after antibody-mediated rejection or glomerulonephritis and 47&#37; of cases of graft loss were identified as being due to nonadherence to treatment&#46;<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">These data reflect changes in the reasons limiting graft half-life after RT&#44; with a tendency towards inadequate control of the immune response &#40;particularly humoral&#41; over the long term&#44; either due to the limited effect of the immunosuppression used or to lack of treatment adherence&#46;</p><p class="elsevierStylePara">Taking these data into consideration&#44; we analyzed what has happened over the last 25 years at our transplant center&#44; starting with the hypothesis that the efficacy of the immunosuppression used is determinant in the long-term results of RT&#46; Indeed&#44; a higher graft survival rate was observed in patients who received a kidney transplant in the second study period &#40;1996-01&#41;&#44; with modern immunosuppression using MMF and TaC&#46; In addition&#44; when MMF was entered instead of study period into our final multivariate model&#44; the use of MMF was associated with a 25&#37; reduction in the risk of graft loss&#46; As a consequence&#44; this has resulted in an increase in uncensored graft half-life of 10&#46;25 years at 14&#46;58 years in those treated with MMF &#40;P&#60;0&#46;001&#41;&#46; These data show a significant change in the long-term results of cadaveric RT in our setting&#46; Furthermore&#44; this effect was independent of the presence of AR and other classical risk factors for graft loss such as donor age&#44; PRA&#44; CIT or DGF&#44; which supports the beneficial effect in terms of graft survival of modern immunosuppression with MMF&#46; Nonetheless&#44; we cannot rule out the potential beneficial effect for graft survival of other factors introduced during the study period 1996-01&#44; such as the increased use of cardioprotective and renoprotective drugs during this period &#40;data not shown&#41;&#46; Further longitudinal studies are needed to clarify this issue&#46;</p><p class="elsevierStylePara">The initial conclusions from the database of the United States Renal Data System on the effect of MMF on graft survival were published in 2000&#46; The study compared&#44; retrospectively&#44; the graft survival of two cohorts of recipients treated with CsA&#43;P plus MMF or Aza &#40;azathioprine&#41;&#46; The conclusion was that censored graft survival at four years was significantly greater in those treated with MMF&#44; with effect from both the time of transplant &#40;85&#46;6&#37; vs&#46; 81&#46;9&#37;&#44; P&#60;0&#46;0001&#41; and from six months after RT &#40;91&#46;4&#37; vs&#46; 89&#46;8&#37;&#44; P&#61;0&#46;002&#41;&#46; The multivariate analysis showed that AR conferred a relative risk 2&#46;41 times greater of developing what&#44; at that time&#44; was defined as chronic allograft nephropathy&#44; whereas the absence of AR reduced the risk by 19&#37; in those treated with MMF &#40;RR&#61;0&#46;81&#44; P&#60;0&#46;001&#41;&#46; In addition&#44; treatment with MMF was a protective factor for graft survival&#44; independently of its preventive effect on AR&#44; and for long-term patient survival&#46;<span class="elsevierStyleSup">15</span> These data were confirmed in a study undertaken before ours<span class="elsevierStyleSup">2</span> as well as in the present study&#44; which provides longer-term follow-up data and shows the continued reduction in graft loss during the whole post-transplant period in those patients who received MMF in association with a CNI&#46;</p><p class="elsevierStylePara">In patients with biopsy-confirmed interstitial fibrosis and tubular atrophy&#44; the addition of MMF reduced progression of worsening renal function&#44; independently of plasma CsA levels&#46;<span class="elsevierStyleSup">16</span> MMF treatment has also been associated with substantially reduced fibrosis in the glomerular&#44; microvascular and interstitial compartments&#44;<span class="elsevierStyleSup">17</span> all determinant factors in long-term renal function&#46;</p><p class="elsevierStylePara">These observations suggest that the addition of MMF to a CNI will achieve a better control of the humoral response&#44; the cause currently thought to be the main factor responsible for long-term graft loss&#46;<span class="elsevierStyleSup">8</span> Indeed&#44; there is clinical and experimental evidence that treatment with MMF inhibits antibody formation&#46; Kidney transplant patients who received triple-drug therapy with CsA&#43;P&#43;MMF had reduced antibody levels to the influenza vaccine compared with those who received triple-drug therapy with Aza&#59;<span class="elsevierStyleSup">18</span> and in patients receiving an ABO-mismatched kidney transplant&#44; the administration of MMF reduced the formation of anti-blood type IgG&#44; which is increased after withdrawal of MMF<span class="elsevierStyleSup">19</span> and treatment with MMF was shown to be superior to Aza in maintaining a renal response to treatment and in preventing relapse in patients with lupus nephritis&#46;<span class="elsevierStyleSup">20</span> However&#44; no significant differences have been found in the rate of graft loss with the use of CsA or TaC plus MMF&#46;</p><p class="elsevierStylePara">Analysis of the renal function in the two study periods is of particular interest&#46; With the increase in donor age and stroke as the cause of death&#44; we would expect worse renal function in the second period &#40;1996-01&#41;&#46; However&#44; the data show the exact opposite&#46; The decline in renal function was significantly less pronounced in the latter period&#44; indicating better preservation of renal function&#46; This may be related with the better control of the immune response&#46;</p><p class="elsevierStylePara">This study is not without limitations&#44; especially those inherent to a single-center retrospective cohort study&#46; In addition&#44; we are unaware of the causes of graft loss in some cases as biopsy findings were not always available&#44; though the renal function was recorded in all cases&#46; Furthermore&#44; the use of newer immunosuppressive agents such as mTor inhibitors was not included as the follow-up period would have been too short&#46; Nevertheless&#44; the study included a rigorous follow-up&#44; with extremely few patients lost to follow-up&#46; Finally&#44; although this study did not include a competitive risk model&#44; survival analyses in large populations over a long period of time &#40;as in this study&#41; guarantee the reliability of the results&#46;<span class="elsevierStyleSup">21</span></p><p class="elsevierStylePara">In conclusion&#44; long-term graft survival improved significantly in the period 1996-2001 as compared with 1986-1995 despite the older age of the donors&#46; Modern immunosuppression&#44; including MMF&#44; has contributed to optimizing RT outcome&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">ACKNOWLEDGMENTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors thank the Nephrology and Urology Unit teams from Carlos Haya University Hospital &#40;Malaga&#44; Spain&#41; for their collaboration&#46; This study was partly supported by the Spanish Ministry of Economy and Competitiveness &#40;MINECO&#41; &#40;Grant no&#46; PI10&#47;01020&#41; from the Instituto de Salud Carlos III&#44; RETICS &#40;REDINREN RD12&#47;0021&#47;0015&#41;&#44; and by Grant PI-0590-2012 &#40;in part&#41; from the Consejer&#237;a de Salud del Gobierno de Andaluc&#237;a&#46;<span class="elsevierStyleBold"> </span>We also thank Ian Johnstone for his linguistic assistance in the preparation of the text&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflict of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the contents of this article&#46;</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52257&#95;en&#95;12327&#95;t1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52257_en_12327_t1.jpg" alt="Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used"></img></a></p><p class="elsevierStylePara">Table 1&#46; Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52258&#95;en&#95;12327&#95;t2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52258_en_12327_t2.jpg" alt="Comparative data for graft loss &#40;attrition rate &#37;&#41; stratified by years post-transplant&#44; for different groups and immunosuppression"></img></a></p><p class="elsevierStylePara">Table 2&#46; Comparative data for graft loss &#40;attrition rate &#37;&#41; stratified by years post-transplant&#44; for different groups and immunosuppression</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52260&#95;en&#95;12327&#95;t4&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52260_en_12327_t4.jpg" alt="Parsimonious Cox proportional hazards multivariate model of factors impacting on graft survival"></img></a></p><p class="elsevierStylePara">Table 4&#46; Parsimonious Cox proportional hazards multivariate model of factors impacting on graft survival</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52261&#95;en&#95;12327&#95;t5&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52261_en_12327_t5.jpg" alt="Course of renal function &#40;mL&#47;min&#47;1&#46;73m2&#41; in transplant patients in the periods 1986-95 and 1996-01"></img></a></p><p class="elsevierStylePara">Table 5&#46; Course of renal function &#40;mL&#47;min&#47;1&#46;73m2&#41; in transplant patients in the periods 1986-95 and 1996-01</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52264&#95;en&#95;12327&#95;f1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52264_en_12327_f1.jpg" alt="Kaplan-Meier uncensored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Kaplan-Meier uncensored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52266&#95;en&#95;12327&#95;f2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52266_en_12327_f2.jpg" alt="Kaplan-Meier censored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"></img></a></p><p class="elsevierStylePara">Figure 2&#46; Kaplan-Meier censored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;59524&#95;en&#95;12327&#95;t3&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_59524_en_12327_t3.jpg" alt="Cox analysis of risk factors for graft loss according to time period"></img></a></p><p class="elsevierStylePara">Table 3&#46; Cox analysis of risk factors for graft loss according to time period</p>"
    "pdfFichero" => "P1-E574-S4691-A12327-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437295"
          "palabras" => array:1 [
            0 => "Vida media del injerto"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437297"
          "palabras" => array:1 [
            0 => "Tasa de p&#233;rdida de injerto"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437299"
          "palabras" => array:1 [
            0 => "Supervivencia del injerto"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437301"
          "palabras" => array:1 [
            0 => "Trasplante renal"
          ]
        ]
      ]
      "en" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437296"
          "palabras" => array:1 [
            0 => "Graft half-life"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437298"
          "palabras" => array:1 [
            0 => "Attrition rates"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437300"
          "palabras" => array:1 [
            0 => "Graft survival"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437302"
          "palabras" => array:1 [
            0 => "Kidney transplantation"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">An&#225;lisis de la vida media del injerto y de su tasa de p&#233;rdida en 1045&#160;transplantes de donantes cad&#225;ver adultos entre 1986 y 2001&#44; con seguimiento hasta 2011&#44; clasificados en dos periodos en funci&#243;n de la inmunosupresi&#243;n&#58; 1986-1995 y 1996-2001&#46; La curva de Kaplan-Meier mostr&#243; un aumento significativo de la supervivencia del injerto durante el periodo 1996-2001&#46; La vida media real no censurada del injerto fue de 10&#44;25 a&#241;os en 1986-1995 y la actuarial fue de 14&#44;58&#160;a&#241;os en 1996-2001 &#40;p&#160;&#60;&#160;0&#44;001&#41;&#46; La tasa de p&#233;rdida del injerto fue significativamente mayor en 1986-1995&#44; incluso con la exclusi&#243;n del primer a&#241;o del an&#225;lisis&#46; En 1996-2001&#44; la disminuci&#243;n de la funci&#243;n renal fue menos pronunciada&#44; observ&#225;ndose una mejor conservaci&#243;n a pesar de que los donantes ten&#237;an m&#225;s edad y de que hab&#237;an fallecido por accidente cardiovascular&#46; El modelo parsimonioso multivariante de Cox revel&#243; que la edad del donante&#44; el rechazo agudo&#44; el panel de anticuerpos reactivos&#44; el tiempo de isquemia fr&#237;a y la funci&#243;n retrasada del injerto se asociaban de forma significativa a un mayor riesgo de p&#233;rdida del injerto&#46; Sin embargo&#44; el riesgo de p&#233;rdida del injerto se vio reducido en un 21&#37; en 1996-2001 en comparaci&#243;n con el periodo 1986-1995&#46; Se observ&#243; una reducci&#243;n similar &#40;25&#37;&#41; al incluir el tratamiento con MMF en el modelo multivariante en lugar del periodo de estudio&#46; La supervivencia del injerto a largo plazo mejor&#243; significativamente en 1996-2001 frente al periodo 1986-1995&#44; a pesar de que los donantes ten&#237;an m&#225;s edad&#46; Por lo tanto&#44; la inmunosupresi&#243;n moderna podr&#237;a haber contribuido a la mejora de los resultados del transplante renal&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">We analyzed graft half-life and attrition rates in 1045 adult deceased donor kidney transplants from 1986-2001&#44; with follow-up to 2011&#44; grouped in two periods &#40;1986-95 vs&#46; 1996-01&#41; according to immunosuppression&#46; The Kaplan-Meier curve showed a significant increase in graft survival during 1996-2001&#46; The uncensored real graft half-life was 10&#46;25 years in 1986-95 and the actuarial was 14&#46;58 years in 1996-2001 &#40;P&#60;0&#46;001&#41;&#46; The attrition rates showed a significantly greater graft loss in 1986-95&#44; even excluding the first year from the analysis&#46; The decline in renal function was significantly less pronounced in 1996-2001&#44; indicating better preservation of renal function&#44; despite the increase in donor age and stroke as the cause of donor death&#46; The parsimonious Cox multivariate model showed donor age&#44; acute rejection&#44; panel reactive antibody&#44; cold ischemia time and delayed graft function were significantly associated with a higher risk of graft loss&#46; In contrast&#44; the risk of graft loss fell by 21&#37; in 1996-2001 compared with 1986-95&#46; A similar reduction &#40;25&#37;&#41; was observed when MMF treatment was entered into the multivariate model instead of study period&#46; Long-term graft survival improved significantly in 1996-2001 compared to 1986-1995 despite older donor age&#46; Modern immunosuppression could have contributed to the improved kidney transplant outcome&#46;</p>"
      ]
    ]
    "multimedia" => array:7 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52257_en_12327_t1.jpg"
            "Alto" => 579
            "Ancho" => 698
            "Tamanyo" => 341081
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52258_en_12327_t2.jpg"
            "Alto" => 308
            "Ancho" => 699
            "Tamanyo" => 196207
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Comparative data for graft loss &#40;attrition rate &#37;&#41; stratified by years post-transplant&#44; for different groups and immunosuppression"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Tab.  4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52260_en_12327_t4.jpg"
            "Alto" => 197
            "Ancho" => 699
            "Tamanyo" => 117644
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Parsimonious Cox proportional hazards multivariate model of factors impacting on graft survival"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Tab.  5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52261_en_12327_t5.jpg"
            "Alto" => 97
            "Ancho" => 702
            "Tamanyo" => 107972
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Course of renal function &#40;mL&#47;min&#47;1&#46;73m2&#41; in transplant patients in the periods 1986-95 and 1996-01"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52264_en_12327_f1.jpg"
            "Alto" => 411
            "Ancho" => 699
            "Tamanyo" => 130029
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Kaplan-Meier uncensored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig6"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52266_en_12327_f2.jpg"
            "Alto" => 410
            "Ancho" => 697
            "Tamanyo" => 132629
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Kaplan-Meier censored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"
        ]
      ]
      6 => array:8 [
        "identificador" => "fig7"
        "etiqueta" => "Tab.  3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_59524_en_12327_t3.jpg"
            "Alto" => 289
            "Ancho" => 699
            "Tamanyo" => 229771
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Cox analysis of risk factors for graft loss according to time period"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:21 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rething our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15268730" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sola E, Gonzalez-Molina M, Cabello M, Burgos D, Ramos J, Gutierrez C, et al. Long-term improvement of deceased donor renal allograft survival since 1996. A single transplant center study. Transplantation 2010;89(6):714-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20035250" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Moreso F, Alonso A, Gentil MA, González-Molina M, Capdevila L, Marcén R, et al. Improvement in late allograft survival between 1990 and 2002 in Spain: results from a multicentre case-control study. Transpl Int 2010;23(9):907-13. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20230537" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20973913" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005;5:1405-14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15888048" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14668458" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al. Evidence for antibody mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90:68-74. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20463643" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22081892" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine. A new predictor equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10075613" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a non renal organ. N Engl J Med 2003;349:931-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12954741" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based inmunosuppression. Transplantation 2007;83:722-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17414704" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigma. Clin J Am Soc Nephrol 2009;4:2029-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19850771" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant 2011;11:687-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21446973" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "El Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9:527-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19191769" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ojo AO, Meier-Kriesche HU, Hanson J, Leichtman AB, Cibrik D, Magee JC, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10868649" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "González-Molina M, Serón D, García del Moral R, Carrera M, Sola E, Jesus Alferez M, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. Transplantation 2004;77:215-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14742984" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nankivell BJ, Wavamunno MD, Borrows RJ, Vitalone M, Fung CL, Allen RD, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007;7:366-76. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17283486" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998;13:160-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9481733" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ishida H, Tanabe K, Furusawa, Ishizuka T, Shimmura H, Tokumoto T, et al. Mycophenolate mofetil suppresses the production of anti-blood types antibodies after renal transplantation across the ABO blood barrier: ELISA to detect humoral activity. Transplantation 2002;74:1187-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12438969" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22087680" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054636/v0_201502091605/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003400000005/v0_201502091605/X2013251414054636/v0_201502091605/en/P1-E574-S4691-A12327-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054636?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Impact of immunosuppression treatment on the improvement in graft survival after deceased donor renal transplantation: a long-term cohort study
Impacto de la inmunosupresión en la mejora de la supervivencia del injerto tras un transplante renal de donante cadáver: estudio de cohorte a largo plazo
Miguel González-Molinaa, Dolores Burgosa, Mercedes Cabelloa, Pedro Ruiz-Estebana, Manuel A. Rodríguezb, Cristina Gutiérreza, Verónica Lópeza, Víctor Baenac, Domingo Hernándeza
a Servicio de Nefrología, Hospital Regional Universitario Carlos Haya/IBIMA, Málaga,
b Servicio de Nefrología, Hospital Torrecárdenas, Almería,
c Servicio de Urología, Hospital Regional Universitario Carlos Haya, Málaga,
Read
12160
Times
was read the article
2557
Total PDF
9603
Total HTML
Share statistics
 array:21 [
  "pii" => "X2013251414054636"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2014.Jun.12327"
  "estado" => "S300"
  "fechaPublicacion" => "2014-09-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:570-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 7324
    "formatos" => array:3 [
      "EPUB" => 336
      "HTML" => 6148
      "PDF" => 840
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699514054639"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2014.Jun.12327"
      "estado" => "S300"
      "fechaPublicacion" => "2014-09-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2014;34:570-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 11353
        "formatos" => array:3 [
          "EPUB" => 323
          "HTML" => 10117
          "PDF" => 913
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "titulo" => "Impacto de la inmunosupresi&#243;n en la mejora de la supervivencia del injerto tras un transplante renal de donante cad&#225;ver&#58; estudio de cohorte a largo plazo"
        "tienePdf" => "es"
        "tieneTextoCompleto" => 0
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "570"
            "paginaFinal" => "578"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Impact of immunosuppression treatment on the improvement in graft survival after deceased donor renal transplantation&#58; a long-term cohort study"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Miguel Gonz&#225;lez-Molina, Dolores Burgos, Mercedes Cabello, Pedro Ruiz-Esteban, Manuel A&#46; Rodr&#237;guez, Cristina Guti&#233;rrez, Ver&#243;nica L&#243;pez, V&#237;ctor Baena, Domingo Hern&#225;ndez"
            "autores" => array:9 [
              0 => array:2 [
                "nombre" => "Miguel"
                "apellidos" => "Gonz&#225;lez-Molina"
              ]
              1 => array:2 [
                "nombre" => "Dolores"
                "apellidos" => "Burgos"
              ]
              2 => array:2 [
                "nombre" => "Mercedes"
                "apellidos" => "Cabello"
              ]
              3 => array:2 [
                "nombre" => "Pedro"
                "apellidos" => "Ruiz-Esteban"
              ]
              4 => array:2 [
                "nombre" => "Manuel A&#46;"
                "apellidos" => "Rodr&#237;guez"
              ]
              5 => array:2 [
                "nombre" => "Cristina"
                "apellidos" => "Guti&#233;rrez"
              ]
              6 => array:2 [
                "nombre" => "Ver&#243;nica"
                "apellidos" => "L&#243;pez"
              ]
              7 => array:2 [
                "nombre" => "V&#237;ctor"
                "apellidos" => "Baena"
              ]
              8 => array:2 [
                "nombre" => "Domingo"
                "apellidos" => "Hern&#225;ndez"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251414054636"
          "doi" => "10.3265/Nefrologia.pre2014.Jun.12327"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054636?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054639?idApp=UINPBA000064"
      "url" => "/02116995/0000003400000005/v0_201502091337/X0211699514054639/v0_201502091337/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251414054628"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Jun.12422"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:579-83"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6136
      "formatos" => array:3 [
        "EPUB" => 301
        "HTML" => 4924
        "PDF" => 911
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Study on overhydration in dialysis patients and its association with inflammation"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "579"
          "paginaFinal" => "583"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Estudio de sobrehidrataci&#243;n en los pacientes en di&#225;lisis y su relaci&#243;n con la inflamaci&#243;n"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12422_16025_61167_en_t112422i.jpg"
              "Alto" => 1723
              "Ancho" => 1074
              "Tamanyo" => 249080
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Descriptive baseline characteristics"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Almudena Vega, Borja Quiroga, Soraya Abad, Caridad Ruiz, Juan M&#46; L&#243;pez-G&#243;mez"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Almudena"
              "apellidos" => "Vega"
            ]
            1 => array:2 [
              "nombre" => "Borja"
              "apellidos" => "Quiroga"
            ]
            2 => array:2 [
              "nombre" => "Soraya"
              "apellidos" => "Abad"
            ]
            3 => array:2 [
              "nombre" => "Caridad"
              "apellidos" => "Ruiz"
            ]
            4 => array:2 [
              "nombre" => "Juan M&#46;"
              "apellidos" => "L&#243;pez-G&#243;mez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054620"
        "doi" => "10.3265/Nefrologia.pre2014.Jun.12422"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054620?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054628?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054628/v0_201502091605/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251414054644"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Apr.12481"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:561-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 10092
      "formatos" => array:3 [
        "EPUB" => 325
        "HTML" => 8826
        "PDF" => 941
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Cardiovascular mortality&#58; how can it be prevented&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "561"
          "paginaFinal" => "569"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Mortalidad cardiovascular&#58; &#191;c&#243;mo prevenirla&#63;"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12481_16025_59949_en_f112481i.jpg"
              "Alto" => 1154
              "Ancho" => 2103
              "Tamanyo" => 434852
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Mediterranean diet pyramid created by the Meditarranean Diet Foundation of Barcelona &#40;2010&#41; &#40;Source&#58; Mediterranean Diet Foundation&#44; www&#46;dfmed&#46;org&#41;22&#46;"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ram&#243;n Estruch, Ramon Estruch"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Ram&#243;n"
              "apellidos" => "Estruch"
            ]
            1 => array:2 [
              "nombre" => "Ramon"
              "apellidos" => "Estruch"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054647"
        "doi" => "10.3265/Nefrologia.pre2014.Apr.12481"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054647?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054644?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054644/v0_201502091605/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Impact of immunosuppression treatment on the improvement in graft survival after deceased donor renal transplantation&#58; a long-term cohort study"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "570"
        "paginaFinal" => "578"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Miguel Gonz&#225;lez-Molina, Dolores Burgos, Mercedes Cabello, Pedro Ruiz-Esteban, Manuel A&#46; Rodr&#237;guez, Cristina Guti&#233;rrez, Ver&#243;nica L&#243;pez, V&#237;ctor Baena, Domingo Hern&#225;ndez"
        "autores" => array:9 [
          0 => array:4 [
            "nombre" => "Miguel"
            "apellidos" => "Gonz&#225;lez-Molina"
            "email" => array:1 [
              0 => "mgonmol&#64;yahoo&#46;es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Dolores"
            "apellidos" => "Burgos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Mercedes"
            "apellidos" => "Cabello"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Pedro"
            "apellidos" => "Ruiz-Esteban"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Manuel A&#46;"
            "apellidos" => "Rodr&#237;guez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Cristina"
            "apellidos" => "Guti&#233;rrez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Ver&#243;nica"
            "apellidos" => "L&#243;pez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "V&#237;ctor"
            "apellidos" => "Baena"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Domingo"
            "apellidos" => "Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => " Servicio de Nefrología, Hospital Regional Universitario Carlos Haya/IBIMA, Málaga,   "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => " Servicio de Nefrología, Hospital Torrecárdenas, Almería,   "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => " Servicio de Urología, Hospital Regional Universitario Carlos Haya, Málaga,   "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Impacto de la inmunosupresi&#243;n en la mejora de la supervivencia del injerto tras un transplante renal de donante cad&#225;ver&#58; estudio de cohorte a largo plazo"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52257_en_12327_t1.jpg"
            "Alto" => 579
            "Ancho" => 698
            "Tamanyo" => 341081
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Since the introduction of cyclosporine &#40;CsA&#41; controversy has surrounded the long-term results of renal transplantation &#40;RT&#41;&#46; The most accepted theory is derived from an observational study of kidney transplant recipients who received their grafts between 1988 and 1995&#59; this study showed a significant increase in graft survival during the first year&#44; but only a marginal increase in the long term&#46;<span class="elsevierStyleSup">1</span> These data demonstrated that&#44; despite CsA reducing the incidence of acute rejection &#40;AR&#41;&#44; RT remained a limited option in terms of survival&#44; with the continued loss of grafts&#46;</p><p class="elsevierStylePara">Other single center<span class="elsevierStyleSup">2</span> and multicenter<span class="elsevierStyleSup">3&#44;4</span> studies including transplant recipients who received their grafts after 1995 and whose immunosuppression included the new agents mycophenolate mofetil &#40;MMF&#41; and tacrolimus &#40;TaC&#41; found an increased long-term graft survival&#44; or at least showed a significant improvement in the rate of decline in long-term kidney allograft function in recent years&#46;<span class="elsevierStyleSup">5</span> In any case&#44; long-term graft loss remained an important problem in kidney transplant recipients&#44; due mainly to calcineurin inhibitor &#40;CNI&#41; toxicity-mediated allograft damage&#46;<span class="elsevierStyleSup">6</span></p><p class="elsevierStylePara">Later&#44; other authors provided data showing that graft loss due to nephrotoxicity was less usual than previously considered&#44; though it was nevertheless common after antibody-mediated rejection&#44; glomerulonephritis and nonadherence to the treatment&#46;<span class="elsevierStyleSup">7&#44;8</span> This represented a new approach to the causes of graft loss&#44; and obliged us to determine whether the introduction of the potent new immunosuppressive agents MMF and TaC improved the results of RT in terms of survival&#46; The aim&#44; therefore&#44; of this study was to assess whether the long-term RT outcome has improved under modern immunosuppression in a cohort study derived from a single transplant center&#46; Given that important immunosuppressive changes occurred in 1996&#44; we arbitrarily divided our cohort population into two periods &#40;1986-1995 and 1996-2001&#41; in order to perform a more detailed and real analysis of factors associated with RT outcome&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">MATERIALS AND METHODS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Study design</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">This retrospective cohort study was carried out at a single transplant center&#46; We pooled data from all adult patients &#40;&#62;18 years&#41; who received a primary or repeat deceased donor transplantation from January 1986 to December 2001 at Carlos Haya University Hospital &#40;Malaga&#44; Spain&#41;&#44; with a follow-up to December 2011&#46; Thus&#44; the minimum and maximum follow-up times were 10 years and 25 years&#44; respectively&#46; Only 17 &#40;1&#46;6&#37;&#41; patients had an incomplete follow-up during the whole study period&#46; Patients with a living donor or double transplant &#40;combined kidney-pancreas or kidney-liver&#41; were excluded&#46;</p><p class="elsevierStylePara">The endpoint of the study was to analyze the graft survival and the attrition rates stratified by year of transplantation in recipients who received different immunosuppressive regimens&#46; We also assessed the patient survival rate and the evolution of renal allograft function&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Immunosuppression</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">Table 1 shows the immunosuppressive treatment in our cohort population by study period&#58; 1986-95 versus 1996-01&#46; Most patients in the first period received CsA plus prednisone &#40;P&#41;&#46; Thereafter&#44; MMF was added in the majority of immunosuppressive treatments&#44; as well as TaC instead of CsA with effect from 1999&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Clinical variables</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The study variables included cause of donor death &#40;trauma or stroke&#41;&#44; age and gender of the donor and the recipient&#44; body mass index&#44; first or retransplantation&#44; time on dialysis&#44; panel-reactive antibody &#40;PRA&#41; at peak and at transplantation&#44; HLA mismatches&#44; cold ischemia time &#40;CIT&#41;&#44; the presence of delayed graft function &#40;DGF&#41;&#44; AR&#44; type of immunosuppressive therapy&#44; graft function&#44; graft and patient survival&#44; graft half-life&#44; and graft attrition rates&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Attrition rates</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">To calculate the attrition rates&#44; we first obtained the actual 0-1 year&#44; 1-3 year&#44; 3-5 year and 5-10 year survival rates&#46; We then subtracted the number of patients with graft failure during the time period from the original number of patients in the cohort&#46; The resulting number was then divided by the original number in the cohort to obtain an absolute failure percentage&#46; This percentage of absolute failures was divided by the total number of years in the follow-up interval&#44; with which we obtained the yearly failure rates&#46;<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Renal function</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The estimated glomerular filtration rate &#40;GFR&#58; mL&#47;min&#46;&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#41;&#44; based on the serum creatinine concentration&#44; was obtained using the abbreviated Modification of Diet in Renal Disease &#40;aMDRD&#41; equation<span class="elsevierStyleSup">9</span> at three months and annually&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Institutional review and patient protection</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">Medical record review was performed according to the Spanish law on clinical data confidentiality&#46; This study was approved by the ethics committee of the hospital and was conducted according to the principles described in the Declaration of Helsinki&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical analyses</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">A descriptive analysis was made&#44; obtaining the mean and the standard deviation for the quantitative variables and the relative frequency for the qualitative variables&#46; Hypothesis contrast tests used included the Student t test or Mann-Whitney test for quantitative variables and the &#935;<span class="elsevierStyleSup">2</span> test or Fisher test for qualitative variables&#46;</p><p class="elsevierStylePara">Kaplan-Meier survival curves were used to assess the unadjusted half-lives and survival rates for both death-censored and uncensored graft survival&#46; The graft half-life was calculated as the median survival&#44; i&#46;e&#46;&#44; the cut point or intersection on the Kaplan-Meier curve with the 50&#37; threshold&#46; The graft half-life was considered to be real if all the patients reached this point and actuarial if only some reached this point&#46; The log-rank test was used to compare survival curves&#46;</p><p class="elsevierStylePara">The Cox proportional regression model was used to estimate the risk factors for graft loss during the follow-up period&#44; with backward stepwise regression&#44; i&#46;e&#46;&#44; starting with all the possible variables and interactions that could influence the model&#46; The variables were then eliminated if their presence failed to improve the quality of the model&#44; choosing always the most parsimonious model&#44; which finally included just those variables giving a more precise prediction&#46;</p><p class="elsevierStylePara">Covariates used to calculate the adjusted Cox multivariate proportional hazards models included donor and recipient age&#44; AR&#44; CIT&#44; DGF&#44; PRA&#44; cause of donor death&#44; HLA mismatches&#44; period of RT &#40;1996-01 vs&#46; 1986-95&#41; and immunosuppression &#40;CsA&#44; MMF&#44; TaC and induction with poly- and monoclonal antibodies&#41;&#46; The proportionality of the exploratory variables in the model was assessed by visual inspection of the log-log survival plots&#46;</p><p class="elsevierStylePara">The statistical analyses were done with SPSS &#40;IBM&#44; Chicago&#44; IL&#44; version 15&#41; for Windows &#40;Microsoft&#44; Redmond&#44; WA&#41;&#44; and EPIDAT 3&#46;1 &#40;Programa para analisis epidemiologico de datos tabulados&#59; Xunta de Galicia&#44; Santiago de Compostela&#44; Spain&#41;&#44; and significance was set at P&#60;0&#46;05&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">We analyzed a total of 1045 adult cadaveric donor kidney transplant recipients between 1986 and 2001&#46; Most of the patient and donor demographic and clinical characteristics varied between the two study periods &#40;Table 1&#41;&#46; Significant increases were found in donor and recipient age&#44; donor death from stroke&#44; and number of HLA mismatches in the second period&#46; In contrast&#44; a significant reduction was seen in PRA&#44; incidence of AR&#44; and CIT in the second period&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Graft survival</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The global actuarial graft half-life was 11&#46;5 years&#46; The real graft half-life in patients with AR was 7&#46;7 years and in those without AR the actuarial graft half-life was 15 years &#40;P&#60;0&#46;001&#41;&#46;</p><p class="elsevierStylePara">The Kaplan-Meier curve showed a significant increase in uncensored and death-censored graft survival during the second period &#40;Figure 1 and Figure 2&#41;&#46; The real uncensored graft half-life was 10&#46;25 years in the first period and the actuarial graft half-life was 14&#46;58 years in the second period &#40;P&#60;0&#46;001&#41;&#46; For the censored cases&#44; the actuarial graft half-life was 14&#46;83 years in the first period&#44; whereas at this point in those patients transplanted during the second period 61&#46;3&#37; still had a functioning graft&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Graft attrition rate &#37;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The attrition rate &#37;&#44; censored and uncensored&#44; showed a continuous loss of grafts over time in both periods&#44; significantly greater in the first period &#40;Table 2&#41;&#46; These differences remained after excluding the first year from the analysis &#40;P&#61;0&#46;0018 and P&#61;0&#46;0001&#44; respectively&#41;&#46; Similarly&#44; patients who received CsA&#43;MMF&#43;P showed a significantly lower rate of graft loss compared with patients on CsA&#43;P in both the uncensored &#40;P&#61;0&#46;0009&#41; and censored &#40;P&#61;0&#46;001&#41; cases&#46; No significant differences were seen in graft survival between CsA and TaC&#46;</p><p class="elsevierStylePara">The Cox univariate and multivariate models showed that donor age and AR were the only risk factors that were significantly associated with graft loss in both periods of the study &#40;Table 3&#41;&#46;</p><p class="elsevierStylePara">The parsimonious Cox multivariate model showed that donor age&#44; AR&#44; PRA&#44; CIT and DGF were significantly associated with a higher risk for graft loss &#40;Table 4&#41;&#46; In contrast&#44; the risk of graft loss fell by 21&#37; in the period 1996-01 compared with the period 1986-95 &#40;Table 4&#41;&#46; Given that most patients &#40;72&#46;20&#37;&#41; transplanted during the period 1996-01 received MMF&#44; we entered into the final model MMF treatment instead of study period&#46; Notably&#44; the use of MMF was associated with a similar reduction in the risk for graft loss &#40;HR 0&#46;758&#44; 95&#37; CI 0&#46;623-0&#46;924&#59; P&#61;0&#46;006&#41;&#44; whereas neither the use of CsA vs&#46; TaC nor induction with poly- and monoclonal antibodies showed significant differences in graft survival&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Patient survival</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">No significant differences were found in patient survival between the two study periods&#46; The 10-year patient survival was 83&#46;2&#37; in the first period and 83&#46;3&#37; in the second period &#40;P&#61;0&#46;432&#41;&#44; even though the recipient age was significantly higher in the latter period&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Renal function</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">The GFR was significantly better in the second period with effect from the third month post-transplant&#46; At this third month post-transplant&#44; a higher GFR was observed in patients transplanted in 1986-95 compared with 1996-01 &#40;51&#46;4&#177;20&#46;0 vs&#46; 48&#46;3&#177;19&#46;6mL&#47;min&#46;&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#59; P&#61;0&#46;01&#41;&#46; However&#44; with effect from the first year post-transplant the renal function was significantly better in the second study period&#44; despite a higher donor age in this period &#40;Table 5&#41;&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">For years the concept has prevailed that graft survival after kidney transplantation has increased in the first year but not over the long term&#46; That is&#44; progress had been made during the early phase of RT&#44; a stage in which T-cell mediated rejection and acute kidney injury predominate&#44;<span class="elsevierStyleSup">8</span> but problems still existed over the longer term that limited the half-life of the graft&#46; Among the causes of this failure&#44; CNI nephrotoxicity was considered a determining factor&#46;<span class="elsevierStyleSup">6</span> This suggestion was supported by authors who found chronic lesions in the native kidneys of recipients of other organs &#40;not kidney&#41; who were treated with CNI&#46;<span class="elsevierStyleSup">10</span></p><p class="elsevierStylePara">Nowadays&#44; though&#44; whilst still recognizing the nephrotoxic effect of CNI&#44; it is not universally accepted that the chronic lesions attributed to CNI are caused solely by these drugs&#46;<span class="elsevierStyleSup">11-13</span> After analyzing the causes of long-term graft loss&#44; others have shown that in cases with fibrosis&#47;atrophy a specific cause was identified in 81&#37; and it was rarely attributable to CNI toxicity alone&#44;<span class="elsevierStyleSup">14</span> cell mediated rejection&#44; or acute kidney injury&#46;<span class="elsevierStyleSup">8</span> Graft loss was&#44; however&#44; more common after antibody-mediated rejection or glomerulonephritis and 47&#37; of cases of graft loss were identified as being due to nonadherence to treatment&#46;<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">These data reflect changes in the reasons limiting graft half-life after RT&#44; with a tendency towards inadequate control of the immune response &#40;particularly humoral&#41; over the long term&#44; either due to the limited effect of the immunosuppression used or to lack of treatment adherence&#46;</p><p class="elsevierStylePara">Taking these data into consideration&#44; we analyzed what has happened over the last 25 years at our transplant center&#44; starting with the hypothesis that the efficacy of the immunosuppression used is determinant in the long-term results of RT&#46; Indeed&#44; a higher graft survival rate was observed in patients who received a kidney transplant in the second study period &#40;1996-01&#41;&#44; with modern immunosuppression using MMF and TaC&#46; In addition&#44; when MMF was entered instead of study period into our final multivariate model&#44; the use of MMF was associated with a 25&#37; reduction in the risk of graft loss&#46; As a consequence&#44; this has resulted in an increase in uncensored graft half-life of 10&#46;25 years at 14&#46;58 years in those treated with MMF &#40;P&#60;0&#46;001&#41;&#46; These data show a significant change in the long-term results of cadaveric RT in our setting&#46; Furthermore&#44; this effect was independent of the presence of AR and other classical risk factors for graft loss such as donor age&#44; PRA&#44; CIT or DGF&#44; which supports the beneficial effect in terms of graft survival of modern immunosuppression with MMF&#46; Nonetheless&#44; we cannot rule out the potential beneficial effect for graft survival of other factors introduced during the study period 1996-01&#44; such as the increased use of cardioprotective and renoprotective drugs during this period &#40;data not shown&#41;&#46; Further longitudinal studies are needed to clarify this issue&#46;</p><p class="elsevierStylePara">The initial conclusions from the database of the United States Renal Data System on the effect of MMF on graft survival were published in 2000&#46; The study compared&#44; retrospectively&#44; the graft survival of two cohorts of recipients treated with CsA&#43;P plus MMF or Aza &#40;azathioprine&#41;&#46; The conclusion was that censored graft survival at four years was significantly greater in those treated with MMF&#44; with effect from both the time of transplant &#40;85&#46;6&#37; vs&#46; 81&#46;9&#37;&#44; P&#60;0&#46;0001&#41; and from six months after RT &#40;91&#46;4&#37; vs&#46; 89&#46;8&#37;&#44; P&#61;0&#46;002&#41;&#46; The multivariate analysis showed that AR conferred a relative risk 2&#46;41 times greater of developing what&#44; at that time&#44; was defined as chronic allograft nephropathy&#44; whereas the absence of AR reduced the risk by 19&#37; in those treated with MMF &#40;RR&#61;0&#46;81&#44; P&#60;0&#46;001&#41;&#46; In addition&#44; treatment with MMF was a protective factor for graft survival&#44; independently of its preventive effect on AR&#44; and for long-term patient survival&#46;<span class="elsevierStyleSup">15</span> These data were confirmed in a study undertaken before ours<span class="elsevierStyleSup">2</span> as well as in the present study&#44; which provides longer-term follow-up data and shows the continued reduction in graft loss during the whole post-transplant period in those patients who received MMF in association with a CNI&#46;</p><p class="elsevierStylePara">In patients with biopsy-confirmed interstitial fibrosis and tubular atrophy&#44; the addition of MMF reduced progression of worsening renal function&#44; independently of plasma CsA levels&#46;<span class="elsevierStyleSup">16</span> MMF treatment has also been associated with substantially reduced fibrosis in the glomerular&#44; microvascular and interstitial compartments&#44;<span class="elsevierStyleSup">17</span> all determinant factors in long-term renal function&#46;</p><p class="elsevierStylePara">These observations suggest that the addition of MMF to a CNI will achieve a better control of the humoral response&#44; the cause currently thought to be the main factor responsible for long-term graft loss&#46;<span class="elsevierStyleSup">8</span> Indeed&#44; there is clinical and experimental evidence that treatment with MMF inhibits antibody formation&#46; Kidney transplant patients who received triple-drug therapy with CsA&#43;P&#43;MMF had reduced antibody levels to the influenza vaccine compared with those who received triple-drug therapy with Aza&#59;<span class="elsevierStyleSup">18</span> and in patients receiving an ABO-mismatched kidney transplant&#44; the administration of MMF reduced the formation of anti-blood type IgG&#44; which is increased after withdrawal of MMF<span class="elsevierStyleSup">19</span> and treatment with MMF was shown to be superior to Aza in maintaining a renal response to treatment and in preventing relapse in patients with lupus nephritis&#46;<span class="elsevierStyleSup">20</span> However&#44; no significant differences have been found in the rate of graft loss with the use of CsA or TaC plus MMF&#46;</p><p class="elsevierStylePara">Analysis of the renal function in the two study periods is of particular interest&#46; With the increase in donor age and stroke as the cause of death&#44; we would expect worse renal function in the second period &#40;1996-01&#41;&#46; However&#44; the data show the exact opposite&#46; The decline in renal function was significantly less pronounced in the latter period&#44; indicating better preservation of renal function&#46; This may be related with the better control of the immune response&#46;</p><p class="elsevierStylePara">This study is not without limitations&#44; especially those inherent to a single-center retrospective cohort study&#46; In addition&#44; we are unaware of the causes of graft loss in some cases as biopsy findings were not always available&#44; though the renal function was recorded in all cases&#46; Furthermore&#44; the use of newer immunosuppressive agents such as mTor inhibitors was not included as the follow-up period would have been too short&#46; Nevertheless&#44; the study included a rigorous follow-up&#44; with extremely few patients lost to follow-up&#46; Finally&#44; although this study did not include a competitive risk model&#44; survival analyses in large populations over a long period of time &#40;as in this study&#41; guarantee the reliability of the results&#46;<span class="elsevierStyleSup">21</span></p><p class="elsevierStylePara">In conclusion&#44; long-term graft survival improved significantly in the period 1996-2001 as compared with 1986-1995 despite the older age of the donors&#46; Modern immunosuppression&#44; including MMF&#44; has contributed to optimizing RT outcome&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">ACKNOWLEDGMENTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors thank the Nephrology and Urology Unit teams from Carlos Haya University Hospital &#40;Malaga&#44; Spain&#41; for their collaboration&#46; This study was partly supported by the Spanish Ministry of Economy and Competitiveness &#40;MINECO&#41; &#40;Grant no&#46; PI10&#47;01020&#41; from the Instituto de Salud Carlos III&#44; RETICS &#40;REDINREN RD12&#47;0021&#47;0015&#41;&#44; and by Grant PI-0590-2012 &#40;in part&#41; from the Consejer&#237;a de Salud del Gobierno de Andaluc&#237;a&#46;<span class="elsevierStyleBold"> </span>We also thank Ian Johnstone for his linguistic assistance in the preparation of the text&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflict of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the contents of this article&#46;</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52257&#95;en&#95;12327&#95;t1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52257_en_12327_t1.jpg" alt="Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used"></img></a></p><p class="elsevierStylePara">Table 1&#46; Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52258&#95;en&#95;12327&#95;t2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52258_en_12327_t2.jpg" alt="Comparative data for graft loss &#40;attrition rate &#37;&#41; stratified by years post-transplant&#44; for different groups and immunosuppression"></img></a></p><p class="elsevierStylePara">Table 2&#46; Comparative data for graft loss &#40;attrition rate &#37;&#41; stratified by years post-transplant&#44; for different groups and immunosuppression</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52260&#95;en&#95;12327&#95;t4&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52260_en_12327_t4.jpg" alt="Parsimonious Cox proportional hazards multivariate model of factors impacting on graft survival"></img></a></p><p class="elsevierStylePara">Table 4&#46; Parsimonious Cox proportional hazards multivariate model of factors impacting on graft survival</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52261&#95;en&#95;12327&#95;t5&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52261_en_12327_t5.jpg" alt="Course of renal function &#40;mL&#47;min&#47;1&#46;73m2&#41; in transplant patients in the periods 1986-95 and 1996-01"></img></a></p><p class="elsevierStylePara">Table 5&#46; Course of renal function &#40;mL&#47;min&#47;1&#46;73m2&#41; in transplant patients in the periods 1986-95 and 1996-01</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52264&#95;en&#95;12327&#95;f1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52264_en_12327_f1.jpg" alt="Kaplan-Meier uncensored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Kaplan-Meier uncensored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;52266&#95;en&#95;12327&#95;f2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_52266_en_12327_f2.jpg" alt="Kaplan-Meier censored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"></img></a></p><p class="elsevierStylePara">Figure 2&#46; Kaplan-Meier censored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;</p><p class="elsevierStylePara"><a href="grande&#47;12327&#95;19904&#95;59524&#95;en&#95;12327&#95;t3&#46;jpg" class="elsevierStyleCrossRefs"><img src="12327_19904_59524_en_12327_t3.jpg" alt="Cox analysis of risk factors for graft loss according to time period"></img></a></p><p class="elsevierStylePara">Table 3&#46; Cox analysis of risk factors for graft loss according to time period</p>"
    "pdfFichero" => "P1-E574-S4691-A12327-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437295"
          "palabras" => array:1 [
            0 => "Vida media del injerto"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437297"
          "palabras" => array:1 [
            0 => "Tasa de p&#233;rdida de injerto"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437299"
          "palabras" => array:1 [
            0 => "Supervivencia del injerto"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437301"
          "palabras" => array:1 [
            0 => "Trasplante renal"
          ]
        ]
      ]
      "en" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437296"
          "palabras" => array:1 [
            0 => "Graft half-life"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437298"
          "palabras" => array:1 [
            0 => "Attrition rates"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437300"
          "palabras" => array:1 [
            0 => "Graft survival"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437302"
          "palabras" => array:1 [
            0 => "Kidney transplantation"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">An&#225;lisis de la vida media del injerto y de su tasa de p&#233;rdida en 1045&#160;transplantes de donantes cad&#225;ver adultos entre 1986 y 2001&#44; con seguimiento hasta 2011&#44; clasificados en dos periodos en funci&#243;n de la inmunosupresi&#243;n&#58; 1986-1995 y 1996-2001&#46; La curva de Kaplan-Meier mostr&#243; un aumento significativo de la supervivencia del injerto durante el periodo 1996-2001&#46; La vida media real no censurada del injerto fue de 10&#44;25 a&#241;os en 1986-1995 y la actuarial fue de 14&#44;58&#160;a&#241;os en 1996-2001 &#40;p&#160;&#60;&#160;0&#44;001&#41;&#46; La tasa de p&#233;rdida del injerto fue significativamente mayor en 1986-1995&#44; incluso con la exclusi&#243;n del primer a&#241;o del an&#225;lisis&#46; En 1996-2001&#44; la disminuci&#243;n de la funci&#243;n renal fue menos pronunciada&#44; observ&#225;ndose una mejor conservaci&#243;n a pesar de que los donantes ten&#237;an m&#225;s edad y de que hab&#237;an fallecido por accidente cardiovascular&#46; El modelo parsimonioso multivariante de Cox revel&#243; que la edad del donante&#44; el rechazo agudo&#44; el panel de anticuerpos reactivos&#44; el tiempo de isquemia fr&#237;a y la funci&#243;n retrasada del injerto se asociaban de forma significativa a un mayor riesgo de p&#233;rdida del injerto&#46; Sin embargo&#44; el riesgo de p&#233;rdida del injerto se vio reducido en un 21&#37; en 1996-2001 en comparaci&#243;n con el periodo 1986-1995&#46; Se observ&#243; una reducci&#243;n similar &#40;25&#37;&#41; al incluir el tratamiento con MMF en el modelo multivariante en lugar del periodo de estudio&#46; La supervivencia del injerto a largo plazo mejor&#243; significativamente en 1996-2001 frente al periodo 1986-1995&#44; a pesar de que los donantes ten&#237;an m&#225;s edad&#46; Por lo tanto&#44; la inmunosupresi&#243;n moderna podr&#237;a haber contribuido a la mejora de los resultados del transplante renal&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">We analyzed graft half-life and attrition rates in 1045 adult deceased donor kidney transplants from 1986-2001&#44; with follow-up to 2011&#44; grouped in two periods &#40;1986-95 vs&#46; 1996-01&#41; according to immunosuppression&#46; The Kaplan-Meier curve showed a significant increase in graft survival during 1996-2001&#46; The uncensored real graft half-life was 10&#46;25 years in 1986-95 and the actuarial was 14&#46;58 years in 1996-2001 &#40;P&#60;0&#46;001&#41;&#46; The attrition rates showed a significantly greater graft loss in 1986-95&#44; even excluding the first year from the analysis&#46; The decline in renal function was significantly less pronounced in 1996-2001&#44; indicating better preservation of renal function&#44; despite the increase in donor age and stroke as the cause of donor death&#46; The parsimonious Cox multivariate model showed donor age&#44; acute rejection&#44; panel reactive antibody&#44; cold ischemia time and delayed graft function were significantly associated with a higher risk of graft loss&#46; In contrast&#44; the risk of graft loss fell by 21&#37; in 1996-2001 compared with 1986-95&#46; A similar reduction &#40;25&#37;&#41; was observed when MMF treatment was entered into the multivariate model instead of study period&#46; Long-term graft survival improved significantly in 1996-2001 compared to 1986-1995 despite older donor age&#46; Modern immunosuppression could have contributed to the improved kidney transplant outcome&#46;</p>"
      ]
    ]
    "multimedia" => array:7 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52257_en_12327_t1.jpg"
            "Alto" => 579
            "Ancho" => 698
            "Tamanyo" => 341081
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Demographic data of the donors and recipients of cadaveric kidney transplants in 1986-2001&#44; separated into two periods according to the study period&#44; with the type of immunosuppression regimen used"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52258_en_12327_t2.jpg"
            "Alto" => 308
            "Ancho" => 699
            "Tamanyo" => 196207
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Comparative data for graft loss &#40;attrition rate &#37;&#41; stratified by years post-transplant&#44; for different groups and immunosuppression"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Tab.  4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52260_en_12327_t4.jpg"
            "Alto" => 197
            "Ancho" => 699
            "Tamanyo" => 117644
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Parsimonious Cox proportional hazards multivariate model of factors impacting on graft survival"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Tab.  5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52261_en_12327_t5.jpg"
            "Alto" => 97
            "Ancho" => 702
            "Tamanyo" => 107972
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Course of renal function &#40;mL&#47;min&#47;1&#46;73m2&#41; in transplant patients in the periods 1986-95 and 1996-01"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52264_en_12327_f1.jpg"
            "Alto" => 411
            "Ancho" => 699
            "Tamanyo" => 130029
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Kaplan-Meier uncensored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig6"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_52266_en_12327_f2.jpg"
            "Alto" => 410
            "Ancho" => 697
            "Tamanyo" => 132629
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Kaplan-Meier censored graft survival according to transplant period &#40;Log-rank test&#44; P&#61;0&#46;000&#41;"
        ]
      ]
      6 => array:8 [
        "identificador" => "fig7"
        "etiqueta" => "Tab.  3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12327_19904_59524_en_12327_t3.jpg"
            "Alto" => 289
            "Ancho" => 699
            "Tamanyo" => 229771
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Cox analysis of risk factors for graft loss according to time period"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:21 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rething our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15268730" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sola E, Gonzalez-Molina M, Cabello M, Burgos D, Ramos J, Gutierrez C, et al. Long-term improvement of deceased donor renal allograft survival since 1996. A single transplant center study. Transplantation 2010;89(6):714-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20035250" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Moreso F, Alonso A, Gentil MA, González-Molina M, Capdevila L, Marcén R, et al. Improvement in late allograft survival between 1990 and 2002 in Spain: results from a multicentre case-control study. Transpl Int 2010;23(9):907-13. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20230537" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20973913" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005;5:1405-14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15888048" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14668458" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al. Evidence for antibody mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90:68-74. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20463643" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12:388-99. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22081892" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine. A new predictor equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10075613" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a non renal organ. N Engl J Med 2003;349:931-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12954741" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based inmunosuppression. Transplantation 2007;83:722-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17414704" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigma. Clin J Am Soc Nephrol 2009;4:2029-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19850771" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant 2011;11:687-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21446973" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "El Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9:527-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19191769" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ojo AO, Meier-Kriesche HU, Hanson J, Leichtman AB, Cibrik D, Magee JC, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10868649" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "González-Molina M, Serón D, García del Moral R, Carrera M, Sola E, Jesus Alferez M, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. Transplantation 2004;77:215-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14742984" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nankivell BJ, Wavamunno MD, Borrows RJ, Vitalone M, Fung CL, Allen RD, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007;7:366-76. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17283486" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998;13:160-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9481733" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ishida H, Tanabe K, Furusawa, Ishizuka T, Shimmura H, Tokumoto T, et al. Mycophenolate mofetil suppresses the production of anti-blood types antibodies after renal transplantation across the ABO blood barrier: ELISA to detect humoral activity. Transplantation 2002;74:1187-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12438969" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22087680" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054636/v0_201502091605/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003400000005/v0_201502091605/X2013251414054636/v0_201502091605/en/P1-E574-S4691-A12327-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054636?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 5 4 9
2024 October 67 31 98
2024 September 58 24 82
2024 August 77 54 131
2024 July 69 31 100
2024 June 74 42 116
2024 May 91 37 128
2024 April 86 35 121
2024 March 63 26 89
2024 February 55 34 89
2024 January 45 25 70
2023 December 60 29 89
2023 November 58 35 93
2023 October 51 39 90
2023 September 57 23 80
2023 August 53 26 79
2023 July 63 29 92
2023 June 52 20 72
2023 May 73 36 109
2023 April 48 15 63
2023 March 67 16 83
2023 February 33 24 57
2023 January 33 23 56
2022 December 71 16 87
2022 November 55 36 91
2022 October 72 33 105
2022 September 92 27 119
2022 August 66 49 115
2022 July 43 38 81
2022 June 50 36 86
2022 May 50 35 85
2022 April 66 42 108
2022 March 45 41 86
2022 February 46 45 91
2022 January 40 36 76
2021 December 48 41 89
2021 November 67 39 106
2021 October 74 46 120
2021 September 56 38 94
2021 August 70 48 118
2021 July 85 33 118
2021 June 51 20 71
2021 May 37 39 76
2021 April 80 72 152
2021 March 91 38 129
2021 February 95 25 120
2021 January 66 18 84
2020 December 36 15 51
2020 November 49 21 70
2020 October 42 20 62
2020 September 30 11 41
2020 August 63 14 77
2020 July 77 16 93
2020 June 89 14 103
2020 May 74 8 82
2020 April 47 21 68
2020 March 61 16 77
2020 February 61 21 82
2020 January 80 23 103
2019 December 69 25 94
2019 November 53 28 81
2019 October 37 14 51
2019 September 70 31 101
2019 August 44 18 62
2019 July 54 30 84
2019 June 50 25 75
2019 May 54 37 91
2019 April 127 38 165
2019 March 54 22 76
2019 February 57 23 80
2019 January 60 34 94
2018 December 96 58 154
2018 November 111 29 140
2018 October 88 13 101
2018 September 96 25 121
2018 August 66 18 84
2018 July 65 18 83
2018 June 61 22 83
2018 May 81 17 98
2018 April 76 15 91
2018 March 76 14 90
2018 February 90 9 99
2018 January 63 17 80
2017 December 74 10 84
2017 November 70 23 93
2017 October 60 17 77
2017 September 55 8 63
2017 August 84 20 104
2017 July 58 13 71
2017 June 63 9 72
2017 May 82 13 95
2017 April 79 23 102
2017 March 45 8 53
2017 February 114 12 126
2017 January 67 12 79
2016 December 106 8 114
2016 November 158 19 177
2016 October 169 10 179
2016 September 256 2 258
2016 August 255 10 265
2016 July 251 11 262
2016 June 184 0 184
2016 May 163 0 163
2016 April 188 0 188
2016 March 161 0 161
2016 February 199 0 199
2016 January 200 0 200
2015 December 171 0 171
2015 November 147 0 147
2015 October 186 0 186
2015 September 138 0 138
2015 August 115 0 115
2015 July 166 0 166
2015 June 89 0 89
2015 May 140 0 140
2015 April 49 0 49
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?